You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Enhancing Situational Awareness to Counter Swarming and Other Nonlinear, Dispersed Tactics Against Naval Surface Forces
SBC: Systems & Technology Research LLC Topic: N122117The Advanced Electronic Development Program (AEDP) will develop prototypes of photonic and digital components. Under AEDP, electronic equipment will be developed and prototyped, with components integrated for a capability demonstration. This work will be performed under the Phase II SBIR program.
SBIR Phase II 2018 Department of DefenseDefense Advanced Research Projects Agency -
TDP-43 aggregation inhibitors for the treatment of ALS
SBC: Aquinnah Pharmaceuticals Inc. Topic: 105Abstract Amyotrophic Lateral SclerosisALSis a universally fatal neurodegenerative disease that afflicts overout of everyindividualsProtein aggregation has been implicated as a primary driving force in ALS and multiple other neurodegenerative illnessesTDPis the principle component of the protein aggregates in ALSand TDPalso stands out as the only genetically defined ALS mutant gene that is also the ...
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Supportive Clinical Trial Tasks for Nanotechnology-Based Treatment of Oral Cancer
SBC: PRIVO TECHNOLOGIES, LLC Topic: NCIPreceding Award: NCI Award 1R44CA192875-02 Project Summary: According to the Oral Cancer Foundation, about 50,000 people in the US will be newly diagnosed with oral cancer (OC) in 2017, causing 9,700 deaths[1]. OC is a severely neglected orphan disease with a lack of significant treatment advances in 4 decades[1]. Historically, OC has been present in heavy smokers and drinkers. However, more recen ...
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
SBIR TOPIC 096:Novel Biodegradable Stents for Neonatal Aortic Coarctation
SBC: Lyra Therapeutics, Inc. Topic: NHLBIAortic coarctation is a common congenital heart condition that is usually recognized during the neonatal period early after birth The usual treatment is open surgery Non surgical catheter based stent therapy is not available to treat neonatal aortic coarctation because children outgrow commercially available metallic stents Absorbable stents might revolutionize the treatment of aortic coarctation ...
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Preclinical development of AST-004 for astrocyte-mediated treatment of TBI.
SBC: ASTROCYTE PHARMACEUTICALS INC. Topic: 103PROJECT SUMMARY Traumatic brain injuriesTBIincluding concussionsare an area of significant unmet need with no approved therapeutics and a national burden of$billion annuallyTBI is the global leading cause of post injury death and disabilityand overmillion Americans sustain a TBI each yearThe tremendous incidence and long term consequences of TBI highlight the considerable epidemic at handand the n ...
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Preclinical development of teixobactin, a new antibiotic
SBC: NOVOBIOTIC PHARMACEUTICALS, LLC Topic: RThe long-term goal of this program is to develop our novel antimicrobial, teixobactin, into a therapeutic for treating a wide range of infections caused by Gram-positive pathogens including Staphylococcus aureus, Streptococcus pneumoniae, Bacillus anthracis, Mycobacterium tuberculosis, Enterococcus faecalis and E. faecium. The goal of this Phase IIB project is to complete preclinical development o ...
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
CLOSURE DEVICE FOR TRANSCAVAL ACCESS TO THE ABDOMINAL AORTA
SBC: TRANSMURAL SYSTEMS LLC Topic: NHLBIProject SummaryAortic stenosis (AS) is a common and lethal cardiac valve disease with an average survival time of only 2 – 3 years after diagnosis if no treatment is obtained. The standard of care for moderate to severe cases of symptomatic AS is surgical valve repair or replacement, which can necessitate open heart surgery. This “gold standard” of care is plagued by substantial limitations, ...
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Risk-based Patient Monitoring for Pediatric Cardiac Patients
SBC: Etiometry Inc. Topic: NHLBIAbstractDuring a successful Phase 2 effort, Etiometry collaborated with multiple world-class pediatric centers to develop, validate, and deploy novel analytics that combine multiple physiologic data streams into a probabilistic assessment of inadequate oxygen delivery to critically ill patients. The analytics were integrated into the Etiometry Platform with the goal of improving physician situatio ...
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
The purpose of this contract is to develop an assay to detect minor populations of resistant variants in blood specimens from HIV-infected individuals with HIV RNA viral loads above 1000 copies/ml
SBC: ALDATU BIOSCIENCES INC Topic: NIAIDAntiretroviral therapyARTreduces mortality and morbidity in HIV infected individualsbut specific HIV mutationsDRMsare associated with resistanceIt is now known that certain DRMs can contribute to virological failure even at very low concentrationsbut standard tests are inadequately sensitive to detect these minor variantsMethods to detect minor variants that contribute to HIV virological failure a ...
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
A Point of Care Test to Monitor and Promote Adherence to Tenofovir-based regimens for the Prevention and Treatment of HIV
SBC: UrSure Inc. Topic: 105PROJECT ABSTRACTThis CRP SBIR project aims to launch to market a point-of-care (POC) test to measure patient adherence to Pre-exposure Prophylaxis (PrEP) as a prevention against HIV infection in people known to be at risk of HIV exposure, and to antiretroviral therapy (ART) as treatment to HIV. HIV contributes to millions of infections and deaths per year and tens of billions of dollars in healthc ...
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health